Clinical Trials Directory
We are doing this study to find out if images taken of the eye using a special type of camera placed inside a surgical microscope, called Microscope Integrated Optical Coherence Tomography (MIOCT), will give us new information during surgery that will improve both how we perform eye surgery and the results of surgery.
We are doing this study to find the most effective, safe dose of an experimental drug called INT230-6 (the study drug) in people with recurrent, inoperable, or metastatic soft tissue sarcomas (STS). We also want to know how well it works compared to the usual treatments for people with this diagnosis.
We are using this registry to learn more about acute aortic dissection from hospitals across the country.
We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.
We are doing this study to learn more about the impact that penile prosthesis devices have on the quality of life with men who have ED.
We are doing this study is to evaluate the outcomes of medial patellofemoral ligament (MPFL) reconstruction surgery. This surgery is a common treatment for recurrent patellofemoral instability. We want to find out what factors most influence the likelihood of this procedure being successful.
We are doing this study to find out if filling the uterus with a soft, experimental material called Juveena Hydrogel (the study product) at the end of gynecological surgical procedures can safely and effectively reduce the formation or reformation of intrauterine adhesions. The device is referred to as a "hydrogel" because it is made of approximately 90% water. The other main ingredient is polyethylene glycol, or "PEG," a material that is widely used in the preparation of drugs and other medical products. The study product will gradually break down over time (within approximately 2 to 3 weeks), so no other procedure is needed to remove it.
We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.